Trial Profile

Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fampridine (Primary)
Indications Ataxia; Multiple sclerosis; Parkinson's disease; Spinal cord injuries; Spinocerebellar degeneration
Focus Pharmacodynamics; Proof of concept
Acronyms Fampyr_2020

Most Recent Events

05 Dec 2024 Planned End Date changed from 31 Dec 2021 to 31 Dec 2041.
05 Dec 2024 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2041.
05 Dec 2024 Planned initiation date changed from 1 Oct 2020 to 1 Jan 2040.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com